Merck KGaA, Darmstadt Clinical Trials

Company details

Status: Public
HQ: Frankfurter Str. 250, Darmstadt, 64293, DE
Employees: 7,364
Programs: 63
Drugs: 50
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target? Jun 6, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for Merck KGaA, Darmstadt.

Trial registry

66 studies

NCT00101998
alvimopan

Phase 2 completed small_molecule

Constipation

CT.gov ↗
NCT00148798
cetuximab + cisplatin + vinorelbine

Phase 3 completed small_molecule

Non Small Cell Lung Cancer (NSCLC)

CT.gov ↗
NCT00778830
Cetuximab

Phase 2 completed small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT01084265
Recombinant human luteinizing hormone (r-hLH)

Phase 3 completed small_molecule

Hypogonadism

CT.gov ↗
NCT01190436
Bisoprolol

Approved completed small_molecule

Hypertension

CT.gov ↗
NCT01832506
MSC2156119J

Phase 1 completed small_molecule

Solid Tumors

CT.gov ↗
NCT02861573
Pembrolizumab 200 mg

Phase 2 active mab

Metastatic Castration-Resistant Prostate Cancer

CT.gov ↗
NCT03036488
Pembrolizumab

Phase 3 completed mab

Triple Negative Breast Neoplasms

CT.gov ↗
NCT03094832
Miransertib

Phase 2 terminated small_molecule

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

CT.gov ↗
NCT03142334
Pembrolizumab

Phase 3 completed mab

Renal Cell Carcinoma

CT.gov ↗
NCT03396445
Boserolimab

Phase 1 completed small_molecule

Pharmacokinetics

CT.gov ↗
NCT03486873
Pembrolizumab

Phase 3 active small_molecule

Solid Tumors

CT.gov ↗
NCT03515837
pembrolizumab

Phase 3 completed mab

Non-small Cell Lung Cancer

CT.gov ↗
NCT03516981
Pembrolizumab

Phase 2 completed mab

Advanced Non-Small Cell Lung Cancer

CT.gov ↗
NCT03547167
V114

Phase 3 completed mab

Pneumococcal Infections

CT.gov ↗
NCT03615326
Pembrolizumab

Phase 3 completed mab

Gastric Neoplasms

CT.gov ↗
NCT03620162
Prevnar 13™

Phase 3 completed mab

Pneumococcal Infections

CT.gov ↗
NCT03631784
Pembrolizumab 200 mg

Phase 2 completed small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT03635567
Pembrolizumab

Phase 3 completed mab

Cervical Cancer

CT.gov ↗
NCT03643952
Daptomycin for Injection

Phase 2 completed small_molecule

Bacteremia

CT.gov ↗
NCT03667547
Raltegravir

Approved completed small_molecule

Human Immunodeficiency Virus (HIV) Infection

CT.gov ↗
NCT03715205
Pembrolizumab

Approved completed small_molecule

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT03725059
Pembrolizumab (K)

Phase 3 active mab

Breast Cancer

CT.gov ↗
NCT03740165
Pembrolizumab

Phase 3 completed mab

Ovarian Cancer

CT.gov ↗
NCT03829332
pembrolizumab

Phase 3 completed mab

Non-small Cell Lung Cancer

CT.gov ↗
NCT04193215
V114

Phase 3 completed mab

Acute Otitis Media (AOM)

CT.gov ↗
NCT04241185
Pembrolizumab

Phase 3 active small_molecule

Urinary Bladder Neoplasms

CT.gov ↗
NCT04246177
Lenvatinib

Phase 3 completed small_molecule

Carcinoma, Hepatocellular

CT.gov ↗
NCT04295772
DOR/ISL

Phase 2 completed small_molecule

HIV-1 Infection

CT.gov ↗
NCT04303169
Pembrolizumab

Phase 2 completed mab

Melanoma

CT.gov ↗
NCT04338061
Teriflunomide

Phase 3 terminated small_molecule

Relapsing Multiple Sclerosis

CT.gov ↗
NCT04375800
Doravirine

Phase 2 active small_molecule

Human Immunodeficiency Virus (HIV) Infection

CT.gov ↗
NCT04489771
Belzutifan

Phase 2 active small_molecule

Carcinoma, Renal Cell

CT.gov ↗
NCT04575584
Molnupiravir

Phase 3 active small_molecule

Coronavirus Disease (COVID-19)

CT.gov ↗
NCT04634877
Pembrolizumab

Phase 3 active mab

Endometrial Neoplasms

CT.gov ↗
NCT04725188
Pembrolizumab/Vibostolimab coformulation

Phase 2 completed mab

Metastatic Non Small Cell Lung Cancer

CT.gov ↗
NCT04736706
Pembrolizumab

Phase 3 active mab

Carcinoma, Renal Cell

CT.gov ↗
NCT04738487
Pembrolizumab/Vibostolimab

Phase 3 completed mab

Lung Neoplasms

CT.gov ↗
NCT04767373
Clesrovimab

Phase 3 completed mab

Respiratory Syncytial Virus Infection

CT.gov ↗
NCT04944992
Efinopegdutide 20 mg/mL

Phase 2 completed small_molecule

Nonalcoholic Fatty Liver Disease

CT.gov ↗
NCT04949256
Pembrolizumab

Phase 3 active mab

Metastatic Esophageal Squamous Cell Carcinoma

CT.gov ↗
NCT05064059
favezelimab/pembrolizumab

Phase 3 completed mab

Colorectal Cancer

CT.gov ↗
NCT05093933
Vericiguat

Phase 3 completed small_molecule

Chronic Heart Failure With Reduced Ejection Fraction

CT.gov ↗
NCT05298423
pembrolizumab/vibostolimab

Phase 3 active mab

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT05319730
Paclitaxel

Phase 2 active small_molecule

Esophageal Squamous Cell Carcinoma

CT.gov ↗
NCT05540327
M5049 low dose

Phase 2 active small_molecule

Systemic Lupus Erythematosus

CT.gov ↗
NCT05766501
DOR/ISL

Phase 3 active small_molecule

HIV Infection

CT.gov ↗
NCT05877547
Efinopegdutide

Phase 2 completed small_molecule

Non-alcoholic Fatty Liver Disease

CT.gov ↗
NCT06041802
Pembrolizumab (+) Berahyaluronidase alfa

Phase 2 active mab

Squamous Cell Carcinoma

CT.gov ↗
NCT06052059
IV Tulisokibart

Phase 3 active small_molecule

Ulcerative Colitis

CT.gov ↗
NCT06074588
Sacituzumab tirumotecan

Phase 3 active mab

Non-small Cell Lung Cancer (NSCLC)

CT.gov ↗
NCT06136559
Nemtabrutinib

Phase 3 active small_molecule

Chronic Lymphocytic Leukemia

CT.gov ↗
NCT06161116
MK-6194

Phase 2 terminated mab

Systemic Lupus Erythematosus

CT.gov ↗
NCT06305754
Sacituzumab tirumotecan

Phase 3 active mab

Non-small Cell Lung Cancer (NSCLC)

CT.gov ↗
NCT06312137
Sacituzumab tirumotecan

Phase 3 active mab

Non Small Cell Lung Cancer

CT.gov ↗
NCT06312176
Sacituzumab tirumotecan

Phase 3 active small_molecule

Breast Neoplasms

CT.gov ↗
NCT06430801
IV Tulisokibart

Phase 3 active small_molecule

Crohn's Disease

CT.gov ↗
NCT06667700
Molnupiravir

Phase 3 active small_molecule

Coronavirus Disease (COVID-19)

CT.gov ↗
NCT06717347
Zilovertamab vedotin

Phase 3 active mab

Diffuse Large B-Cell Lymphoma

CT.gov ↗
NCT06721156
MK-1167

Phase 2 active small_molecule

Alzheimer Disease

CT.gov ↗
NCT06863272
Docetaxel

Phase 2 active small_molecule

Castration-Resistant Prostatic Cancer

CT.gov ↗
NCT06864169
Raludotatug Deruxtecan (R-DXd)

Phase 2 active mab

Gastrointestinal Cancer

CT.gov ↗
NCT06961006
Intismeran autogene

Phase 2 active mab

Malignant Melanoma

CT.gov ↗
NCT07013487
V181

Phase 3 active mab

Healthy

CT.gov ↗
NCT07033494
MK-2214

Phase 2 active mab

Early Alzheimer's Disease

CT.gov ↗
NCT07044297
MK-8527

Phase 3 active small_molecule

Human Immunodeficiency Virus (HIV)

CT.gov ↗

Recent trial activity

Trial registry

Stay Ahead in Pharma